Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2016 16:30 ET | Source: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the Full Year of 2015

SALT LAKE CITY, March 10, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31,...
March 08, 2016 08:00 ET | Source: Lipocine Inc.

Lipocine to Present at 28th Annual Roth Conference

SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
February 16, 2016 07:00 ET | Source: Lipocine Inc.

Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women

Relevant hydroxyprogesterone caproate levels achieved following oral administrationAmenable to dose adjustment while on therapyWell tolerated with no serious adverse events or adverse drug reactions...
January 04, 2016 09:00 ET | Source: Lipocine Inc.

Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy

SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical...
November 24, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine to Present at 27th Annual Piper Jaffray Healthcare Conference

SALT LAKE CITY, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
November 13, 2015 16:00 ET | Source: Lipocine Inc.

Lipocine Adopts Stockholder Rights Plan

SALT LAKE CITY, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a...
November 12, 2015 16:02 ET | Source: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the Third Quarter of 2015

SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as well...
November 12, 2015 16:00 ET | Source: Lipocine Inc.

Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA

SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has assigned a...
November 11, 2015 16:00 ET | Source: Lipocine Inc.

Lipocine Announces Presentation of LPCN 1021 Clinical Data at 21st Annual SMSNA Meeting

SALT LAKE CITY, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone product...
October 29, 2015 16:00 ET | Source: Lipocine Inc.

FDA Accepts for Filing Lipocine’s New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

SALT LAKE CITY, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has accepted...